Introduction {#S1}
============

Atopic dermatitis (AD) is the most common skin diseases in the pediatric population that affects about 15--30% children and adolescents worldwide ([@B4]). AD mostly occurs in early childhood, which is a critical period of life for physical and psychological development ([@B12]). The complex pathogenesis of AD may underpin the lack of effective medical treatment for many cases, with one-third of affected children continuing to experience symptoms in adolescence ([@B40]).

The link between pediatric AD and mental disorders, especially attention-deficit/hyperactivity disorder (ADHD), has attracted increasing attention in the past decade, due to parallel rises in their global prevalence ([@B41]). Also, mental disorders and skin diseases are in the top 20 conditions with the highest personal healthcare costs for children and adolescents in some developed countries such as the United States ([@B13]). It is becoming more apparent that healthcare professionals should understand the psychological effects on children of suffering AD in order to treat it successfully ([@B24]).

However, the overall trends of mental disorders in children with AD are not clear. Important knowledge gaps exist in the area of research. There are inconsistent findings regarding the risk of mental disorders in children with AD ([@B19]; [@B32]). Most previous research has focused on associations between pediatric AD and one mental disorder only generally ADHD ([@B28]; [@B46]). A recent systematic review found the positive association between pediatric AD and depression ([@B44]). However, it did not assess the risk of other important types of mental disorders in children with eczema such as anxiety, autism spectrum disorder (ASD), and conduct disorder, etc. Some relevant studies may be not included in this review since it only searched three medical databases. Moreover, no study to date has compared the risks of different types of mental disorders in children with AD. Additionally, previous research has suggested that AD prevalence is associated with demographic factors such as age, gender ([@B16]), race/ethnicity ([@B54]); socioeconomic factors such as family socioeconomic status (SES) ([@B39]), and country SES ([@B59]). Yet, no study has attempted to explore the impact of these potential confounders on the association between pediatric AD and mental disorders. Understanding different circumstances and contexts is essential when planning holistic health care for children suffering AD.

Therefore, this paper describes the findings of a systematic literature review and meta-analysis. Its objectives were to: (1) systematically review the available evidence and assess whether children and adolescents with AD have higher risks of mental disorders than children who do not suffer from AD; (2) determine risks of specific mental disorders for children suffering AD; and (3) analyze the effect of potential confounders by seeking differences in effect sizes related to participant and study characteristics.

Materials and Methods {#S2}
=====================

Protocol and Registration {#S2.SS1}
-------------------------

The study followed the systematic review protocol PROSPERO 2018: CRD42018087957 ([@B66]). Findings were reported using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses diagnostic test accuracy (PRISMA-DTA) guideline ([@B38]).

Eligibility Criteria {#S2.SS2}
--------------------

English-language published, peer-reviewed scientific articles reporting primary experimental or observational studies were potentially eligible for inclusion. Studies should: (1) target children and adolescents (≤18 years old); (2) assess mental disorders categorized by the Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-5; [@B3]) or outcome domains identified as "mental health problems" or "psychiatric disorders," etc.; (3) compare the prevalence and/or incidence of mental disorders between children or adolescents with AD, and those without AD; and (4) apply quantitative research methods and report effect sizes, or data that could be extracted to compute effect sizes. Excluded were conference abstracts, secondary evidence or case reports.

Information Sources {#S2.SS3}
-------------------

A systematic search of eight electronic databases was undertaken in September 2018, including EMBASE (from 1974), MEDLINE (from 1946), PsycINFO (from 1806), ERIC (from 1966), Social Work Abstracts (from 1968), Family and Society Studies Worldwide (from 1970), British Nursing Index (from 1994), and Sociological Abstracts (from 1952). The authors believed that these databases were most likely to contain papers appropriate to this review.

Search {#S2.SS4}
------

Three groups of search terms were used in combination and modified according to the requirements of the electronic databases: (1) AD (eczema OR atopic dermatitis OR atopic eczema OR neurodermatitis); (2) children (child^\*^ OR boys OR girls OR juvenil^\*^ OR minors OR adolesc^\*^ OR preadolesc^\*^ OR pre-adolesc^\*^ OR pre-school OR preschool OR pediatric^\*^ OR pediatric^\*^ OR pubescen^\*^ OR puberty OR school^\*^ OR campus OR teen^\*^ OR young OR youth^\*^); and (3) mental disorders (psychiatri^\*^ OR psycho^\*^ OR mental OR depress^\*^ OR anxiet^\*^ OR disorder^\*^ OR therap^\*^ OR counsel^\*^). Search dates were from database inception to Dec 6, 2017. A final prepublication search of these databases was undertaken from Oct 1, 2017 to Sep 30, 2018. The reference lists of previous systematic reviews were hand-searched ([@B21]; [@B48]; [@B46]; [@B44]). All records were incorporated into this study.

Study Selection {#S2.SS5}
---------------

All records were exported into EndNote software (EndNote, [RRID:SCR_014001](https://scicrunch.org/resolver/RRID:SCR_014001)). Two investigators (Q-WX and XT) independently screened titles and abstracts for eligibility, and two investigators (Q-WX and XD) independently assessed full texts of potentially relevant studies. Differences were resolved by discussing with a third investigator.

Data Collection Process {#S2.SS6}
-----------------------

Information on participant and study characteristics was independently extracted by two investigators (Q-WX and XD) by using a pre-piloted, standardized coding scheme ([Table 1](#T1){ref-type="table"}), demonstrating a high level of inter-rater agreement (mean Cohen's Kappa = 0.90).

###### 

Coding scheme.

  **No.**   **Variable**                       **Definitions and Conditions**
  --------- ---------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------
  A         Sample size                        Numbers of participants in AD group/Non-AD group
  B         Age of child (mean)                Mean age (years) of participated children in total sample
  C         Age of child (range)               Range of age of participated children in total sample
  D         Sex of child                       Percentage of females in total sample
  E         Race/ethnicity of child            Percentage of racial or ethnic minorities in total sample
  F         Asthma                             Percentage of children who were identified as having asthma by the included study in AD group/Non-AD group
  G         Home SES                           Percentage of families which were defined as low SES by the included study in total sample
  H         Location                           Country or territory in which the study was conducted
  I         Type of study                      1 = cohort, 2 = case-control, 3 = cross sectional
  J         Representativeness of the sample   1 = convenience sample or clinical sample, 2 = random sample or community sample
  K         Target of comparison               Nature of the Non-AD group (1 = healthy control, 2 = general population, 3 = people with other conditions)
  L         Equivalence                        Equivalence of AD group and Non-AD group (1 = yes, 2 = no)
  M         Assessment of AD                   Method employed to identify AD of participants (1 = diagnosed by a doctor or professional, 2 = self/parental report of doctoral diagnosis, 3 = questionnaire)
  N         Assessment of quality              Total score calculated according to the Newcastle-Ottawa Quality Assessment Forms
  O         Outcome domains                    Type of mental disorders of participated children identified by the included study
  P         Measurement of outcome             Name of scales or other methods used to measure the mental disorders of participated children
  Q         Rater of outcomes                  People who rate the mental disorders of participated children (1 = child/adolescent, 2 = parent/caregiver, 3 = clinician)
  R         Original metric                    Original data used to calculate effect sizes (1 = OR, 2 = mean and SD, 3 = rates or events)

Data of follow-up tests in cohort study; AD, Atopic dermatitis; OR, odds ratio; SD, standard deviation; SES, socioeconomic status.

Risk of Bias, and Applicability {#S2.SS7}
-------------------------------

Two investigators (Q-WX and XD) independently assessed the methodological quality of each study using the Newcastle-Ottawa Scale (NOS) for case-control and cohort studies ([@B65]), and cross-sectional studies ([@B27]). The NOS assess three domains of quality for each included study, including the selection of sample, the section of comparability, and exposure or outcome. The highest score was 9 for a study when it satisfied all criteria.

Synthesis of Results and Meta-Analysis {#S2.SS8}
--------------------------------------

All calculations were performed using Comprehensive Meta-Analysis (CMA, [RRID:SCR_012779](https://scicrunch.org/resolver/RRID:SCR_012779)) software and applying the random-effects models given the heterogeneity of the included studies ([@B36]). A meta-analysis was performed to calculate an overall effect size of all studies combined, to illustrate the risk of *Total Mental Disorders* in children with AD, compared to those without AD. To do this, effect size ORs were first computed for each study. When one type of mental disorder was measured by multiple tests, findings were combined by averaging the effect sizes within that study. When a study contained more than one outcome domain, effect sizes of different outcome domains were aggregated by averaging means to generate a combined effect size. This avoided the risk of including more than one effect size per construct per sample ([@B36]; [@B10]). Independent meta-analyses were performed, and subtotal effect sizes of relevant studies were combined to illustrate the risks of specific types of mental disorders (e.g., ADHD, sleep disorders, anxiety, depression, etc.) in children with AD, compared to those without AD. Crude odds ratios (ORs) were used to compare the relative likelihood of the occurrence of mental disorders, given exposure to AD. Precision of effect sizes was reported by 95% Confidence Intervals (CIs). A combined effect size was considered significant if the CI did not include 1 and the *p*-value was significant in the *Z*-test.

Additional Analyses {#S2.SS9}
-------------------

### Assessment of Heterogeneity {#S2.SS9.SSS1}

Heterogeneity across studies was computed using the Q statistic and quantified by the I-squared (*I*^2^) value ([@B10]).

### Sensitivity Analyses {#S2.SS9.SSS2}

We performed sensitivity analyses by removing studies one-by-one to estimate the strength of association between pediatric AD and mental disorders.

### Assessment of Publication Bias {#S2.SS9.SSS3}

Omitting unpublished studies from this meta-analysis could bias the estimates of risk of mental disorders in children with AD, because studies with significant findings might have more opportunities to be published in peer-reviewed journals than studies with Non-significant findings. Possible publication bias was tested using funnel plot asymmetry ([@B10]) and quantified by the Egger's test ([@B58]). The unbiased effect size was calculated using the trim and fill approach. The Rosenthal's fail-safe number was applied to indicate the number of potentially missing studies with Non-significant results, that would have to be included in the meta-analysis before the *p*-value became Non-significant.

### Subgroup Analysis {#S2.SS9.SSS4}

Each type of mental disorder was treated independently. Each outcome domain was also treated as an independent correlate, by comparing effect sizes for different types of mental disorders in children with AD, compared to those without AD.

### Meta-Regression Analysis and Moderator Analysis {#S2.SS9.SSS5}

By using mixed effects models, the effect of potential confounders (moderators) were explored to explain the variability in effect sizes of *Total Mental Disorder* if the assumption of homogeneity between studies was rejected. Moderator analysis was conducted for categorical variables by comparing effect sizes for studies grouped by study classification, on the potential moderator.

Results {#S3}
=======

Study Selection {#S3.SS1}
---------------

The electronic database search identified 5,788 records. Hand-searching reference lists of earlier systematic reviews yielded six additional relevant studies. After de-duplication, 3,452 studies remained for title and/or abstract screening, following which 3,207 studies were excluded as not being relevant. Further excluded were 200 studies after the full-texts of 245 potentially eligible studies had been reviewed. Thirty-seven studies were selected after full-text screening. Two papers only provided adjusted hazard ratios (HRs) from which effect sizes could not be determined ([@B19]; [@B42]). Sensitivity analyses (conducted by removing papers one at a time) indicated no significant change of the overall results. Therefore, thirty-five studies were included in the current meta-analysis. [Figure 1](#F1){ref-type="fig"} outlines the process of study selection.

![Selection of articles for inclusion.](fpsyg-10-01773-g001){#F1}

Study Characteristics {#S3.SS2}
---------------------

[Table 2](#T2){ref-type="table"} presents characteristics of participants and studies. Outcomes and measures are reported in [Table 3](#T3){ref-type="table"}.

###### 

Characteristics of participants and studies.

  **Study name**   **A**           **B**   **C**    **D**   **E**   **F**       **G**   **H**                **I**   **J**   **K**   **L**   **M**   **N**
  ---------------- --------------- ------- -------- ------- ------- ----------- ------- -------------------- ------- ------- ------- ------- ------- -------
  [@B1]            30/30           9.3     5--15    51.7    53.5    47.0/10.0   21.5    United Kingdom^\*^   2       1       3       1       1       6
  [@B5]            30354/263827    NR      0--18    48.8    NR      NR          NR      Germany^\*^          3       2       3       2       1       6
  [@B8]            81/81           NR      5--12    NR      NR      NR          NR      NR                   2       NR      NR      1       NR      3
  [@B11]           3152/11045      9.0     9        49.6    NR      NR          NR      Sweden^\*^           1       2       2       2       3       6
  [@B14]           15/15           11.9    9--14    53.3    NR      NR          NR      Germany^\*^          2       1       1       1       1       7
  [@B15]           77/30           9.9     6--16    50.2    NR      NR          NR      Australia^\*^        2       1       1       1       1       6
  [@B17]           80/74           2.1     3--      48.6    NR      NR          28.6    Turkey               2       1       2       1       1       3
  [@B18]           84/473          4.8     3--7     48.7    NR      NR          40.7    Korea^\*^            3       2       2       2       3       7
  [@B22]           325/2867        15.1    10--18   43.4    100     NR          16.9    Korea^\*^            3       2       2       2       2       8
  [@B23]           508/2648        8.0     8        49.7    NR      NR          NR      Sweden^\*^           1       2       2       2       1       7
  [@B26]           200/570         11.0    11       50.1    NR      NR          NR      Germany^\*^          1       2       2       2       1       8
  [@B28]           840/900         10.2    2--18    49.2    NR      NR          43.5    Israel^\*^           2       1       3       1       1       7
  [@B29]           1178/2428       NR      10--18   49.4    NR      NR          16.4    Sweden^\*^           1       2       2       2       2       9
  [@B30]           994/5121        12.9    13       53.2    2.0     NR          NR      United Kingdom^\*^   1       2       2       1       2       7
  [@B31]           1641/8313       NR      7--14    50.0    100     NR          NR      Japan^\*^            3       2       2       2       3       7
  [@B32]           18473/18473     NR      3--13    46.2    100     38.3/17.1   NR      Taiwan^\*^           2       2       3       1       1       9
  [@B33]           4904/67531      NR      12--17   53.0    100     NR          10.9    Korea^\*^            3       2       2       1       2       8
  [@B34]           387262/387262   NR      6--10    47.4    100     NR          30.3    Taiwan^\*^           1       2       3       1       1       9
  [@B35]           1030/2320       NR      15--16   56.7    NR      NR          2.4     Norway^\*^           3       1       2       2       3       7
  [@B43]           1952/11366      9.9     3--17    50.4    NR      12.6/3.9    25.6    Germany^\*^          3       2       2       2       2       8
  [@B45]           22/20           4.8     3--9     40.5    NR      NR          NR      India                2       1       1       1       1       6
  [@B51]           1436/1436       12.6    6--17    59.9    NR      10.3/2.9    NR      Germany^\*^          2       2       3       1       1       7
  [@B47]           780/2136        10.0    10       49.0    NR      12/5        8       Germany^\*^          1       2       2       2       1       7
  [@B50]           367/1162        10.0    10       48.5    NR      11/4        14      Germany^\*^          1       2       2       1       2       8
  [@B49]           42/47           9.9     6--12    36.5    NR      NR          11.4    Germany^\*^          3       1       1       2       1       5
  [@B52]           57/37           7.0     4--10    50.8    NR      NR          NR      Israel^\*^           2       1       1       2       1       4
  [@B53]           10620/178093    NR      0--17    47.8    100     NR          NR      Taiwan^\*^           1       2       3       2       1       9
  [@B55]           10333/69334     8.0     0--17    49.1    45.2    25.1/12.3   17.9    United States^\*^    3       2       2       2       2       7
  [@B56]           48/197          13.0    13       34.7    11      NR          NR      United States^\*^    1       2       3       2       3       7
  [@B60]           33808/302955    NR      2--17    NR      NR      NR          NR      United States^\*^    1       2       2       2       2       7
  [@B2]            36/36           11.6    9--16    41.7    NR      NR          NR      Turkey               2       1       2       1       1       5
  [@B63]           340/454         6.8     4--10    NR      100     NR          NR      \#                   2       1       1       1       1       7
  [@B64]           95/434          2.0     1--2     48.9    NR      NR          27.3    China                3       1       3       1       1       7
  [@B67]           10401/69095     NR      0--18    48.6    44.5    25.2/NR     18.1    United States^\*^    3       2       2       2       2       7
  [@B68]           411/2361        NR      3--6     46.6    100     NR          32      Taiwan^\*^           3       2       2       2       2       7

\(A\)

, sample size: numbers of participants in AD group/Non-AD group;

\(B\)

, age of child (mean): mean age (years) of participated children in total sample;

\(C\)

, age of child (range): range of age of participated children in total sample;

\(D\)

, sex of child: percentage of females in total sample;

\(E\)

, race/ethnicity of child: percentage of racial or ethnic minorities in total sample;

\(F\)

, asthma: Percentage of children who were identified as having asthma by the included study in AD group/Non-AD group;

\(G\)

, home socioeconomic status (SES): percentage of families which were defined as low SES by the included study in total sample;

\(H\)

, location: country or territory in which the study was conducted;

\(I\)

, type of study: 1 = cohort, 2 = case-control, 3 = cross sectional;

\(J\)

, representativeness of the sample: 1 = convenience sample or clinical sample, 2 = random sample or community sample;

\(K\)

, target of comparison: nature of the Non-AD group, 1 = healthy control, 2 = general population, 3 = people with other conditions;

\(L\)

, equivalence: equivalence of AD group and Non-AD group, 1 = yes, 2 = no;

\(M\)

, assessment of AD: method employed to identify AD of participants; 1, diagnosed by a doctor or professional; 2, self/parental report of doctoral diagnosis; 3, questionnaire;

\(N\)

, assessment of quality: total score calculated according to the Newcastle-Ottawa Quality Assessment Forms; NR, not report;

\#

Nine countries in Latin America including Argentina, Brazil, Colombia, Cuba, Dominican Republic, Honduras, Mexico, Paraguay, and Uruguay;

\*

developed countries or territories defined as those possessing an Human Development Index \[HDI\] over 0.800 according to

United Nations Development Programme \[UNDP\] (2018)

.

###### 

Outcomes and measurements.

  **Study name**   **Outcome domains**                                                                                                                                **Measurement of outcome**                  **Rater of outcomes**                   **Original metric**
  ---------------- -------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------- --------------------------------------- ---------------------
  [@B1]            Psychological disturbance (including sleep disturbance)                                                                                            Rutter A2 scale                             Clinician                               Rates or events
  [@B5]            ADHD, depression                                                                                                                                   Diagnosed                                   Clinician                               OR
  [@B8]            ADHD                                                                                                                                               Parents Rating Scale                        Parent/caregiver                        Rates or events
  [@B11])          Anxiety/depression                                                                                                                                 SCARED, SMFQ                                Parent/caregiver                        OR
  [@B14]           Anxiety                                                                                                                                            Anxiety Inventory for Children              Child/adolescent                        OR
  [@B15]           ADHD, sleep disorder                                                                                                                               SDSC, Conners Parent Rating Scale-Revised   Parent/caregiver                        Mean and SD
  [@B17]           Psychiatric disorders (including ADHD, anxiety, attachment disorder, conduct disorder, eating disorder, ODD, sleep disorders, and tic disorders)   ECI-4                                       Parent/caregiver                        Rates or events
  [@B18]           ADHD, affective disorder, anxiety, externalizing problem, internalizing problem, ODD, PDD, and sleep disorders                                     CBCL                                        Parent/caregiver                        Mean and SD
  [@B22]           Depression                                                                                                                                         Self-designed questionnaire                 Parent/caregiver                        Rates or events
  [@B23]           Anxiety/depression                                                                                                                                 Subscale of EQ-5D                           Parent/caregiver                        Rates or events
  [@B26]           ADHD                                                                                                                                               Diagnosed                                   Clinician                               Rates or events
  [@B28]           ADHD                                                                                                                                               Diagnosed                                   Clinician                               OR
  [@B29]           ADHD                                                                                                                                               Diagnosed                                   Clinician                               OR
  [@B30]           Psychotic experiences                                                                                                                              PLIKSi                                      Child/adolescent                        OR
  [@B31]           Mental health problems (including ADHD, and conduct disorder)                                                                                      SDQ                                         Parent/caregiver                        OR
  [@B32]           ADHD, ASD                                                                                                                                          Diagnosed                                   Clinician                               Rates or events
  [@B33]           Depression                                                                                                                                         Self-designed questionnaire                 Child/adolescent                        Rates or events
  [@B34]           ADHD, ASD                                                                                                                                          Diagnosed                                   Clinician                               Rates or events
  [@B35]           Internalizing and externalizing mental health problems                                                                                             HSCL-10, SDQ                                Child/adolescent                        OR
  [@B43]           ADHD                                                                                                                                               Diagnosed                                   Clinician                               OR
  [@B45]           Psychological disorders (including anxiety, conduct disorder, depression)                                                                          CPMS                                        Parent/caregiver                        Mean and SD
  [@B51]           ADHD, affective disorder, eating disorder, personality disorder                                                                                    Diagnosed                                   Clinician                               Rates or events
  [@B47]           Mental health problems (including ADHD, and conduct disorder)                                                                                      SDQ                                         Parent/caregiver                        OR
  [@B50]           Mental health problems (including ADHD, and conduct disorder)                                                                                      SDQ                                         Parent/caregiver                        OR
  [@B49]           ADHD, mental health problems (including anxiety/depression), and sleep disorders                                                                   Conners 3 Rating Scales, CBCL, CSHQ, SSR    Child/adolescent and parent/caregiver   Mean and SD
  [@B52]           Sleep disorders                                                                                                                                    CSHQ                                        Parent/caregiver                        OR
  [@B53]           ADHD                                                                                                                                               Diagnosed                                   Clinician                               OR
  [@B55]           Sleep disorders                                                                                                                                    Self-designed questionnaire                 Parent/caregiver                        Rates or events
  [@B56]           Anxiety, depression                                                                                                                                HBQ, OCHS                                   Child/adolescent and parent/caregiver   Mean and SD
  [@B60]           Speech disorder                                                                                                                                    Diagnosed                                   Clinician                               Rates or events
  [@B2]            Anxiety                                                                                                                                            STAI-C                                      Child/adolescent                        Mean and SD
  [@B63]           Sleep disorders                                                                                                                                    CSHQ                                        Parent/caregiver                        Mean and SD
  [@B64]           Sleep disorders                                                                                                                                    BISQ                                        Parent/caregiver                        OR
  [@B67]           ADHD, anxiety, ASD, conduct disorder, depression                                                                                                   Diagnosed                                   Clinician                               Rates or events
  [@B68]           ADHD                                                                                                                                               Diagnosed                                   Clinician                               OR

ADHD, attention-deficit/hyperactivity disorder; ASD, autism spectrum disorder; BISQ, Brief Infant Sleep Questionnaire; CBCL, Child Behavior Checklist; CPMS, Childhood Psychopathology Measurement Schedule questionnaire; CSHQ, Children's Sleep Habits Questionnaire; Diagnosed, diagnosed by a doctor or professional; ECI-4, Early Childhood Inventory-4; HBQ, Health and Behavior Questionnaire (parental assessed); HSCL-10, The ten-item version of Hopkins Symptoms Checklist; OCHS, The Ontario Child Health Study scale (self-assessed by child); ODD, oppositional defiant disorder; PDD, pervasive developmental disorder, PLIKSi, Psychosis-like Symptoms interview; SCARED, Child Anxiety Related Emotional Disorders; SDSC, Sleep Disturbance Scale for Children; SMFQ, Shorted Mood and Feelings; SSR, Sleep Self Report (self-assessed by child); STAI-C, State-Trait Anxiety Inventory for Children; OR, odds ratio; SD, standard deviation.

### Characteristics of Participants {#S3.SS2.SSS1}

Data from 1,935,147 children and adolescents (521,976 identified as having AD) were included in this systematic review. Study sample size ranged from *n* = 30 to *n* = 774,524. Participants' mean age was 9.12 years (*SD* = 3.29 years, *k* = 23). Similar numbers of boys and girls were reported (Mean % of females = 48.5%, *k* = 32). Three-quarters of subjects were Non-Caucasian (*M* = 73.6%, *k* = 13), and 10 studies were conducted totally on Asian populations (*n* = 1,089,330). AD diagnosis of children was confirmed by a doctor or other healthcare professional in most studies (*k* = 19). More than 20% of children with AD were also reported as having asthma (*M* = 22.7%, *k* = 8; compared with 7.8% in the Non-AD group. More than 20% of participating families were from low SES circumstances (*M* = 21.5%, *k* = 17). The majority of participants (*k* = 29, *n* = 1,933,466) were recruited from developed countries or territories with high Human Development Index (HDI) scores (8.00 or more; [@B62]).

### Characteristics of Studies {#S3.SS2.SSS2}

Eleven studies were published in 2010 or earlier. All studies applied observational study designs including 11 cohort studies, 12 case control studies, and 12 cross-sectional studies. In terms of representativeness of sample, 22 studies used a random sample or a community sample. Nineteen studies compared the prevalence or incidence of mental disorders in children with AD to the general population, rather than healthy controls.

### Outcomes and Measures {#S3.SS2.SSS3}

Thirteen types of mental disorders were reported in the papers included in this systematic review including: ADHD (*n* = 1,414,406), sleep disorders (*n* = 82,051), anxiety (*n* = 3,881), depression (*n* = 449,591), conduct disorder (*n* = 94,091), autism spectrum disorder (ASD; *n* = 890,966), affective disorder (*n* = 3,429), eating disorder (*n* = 3,026), oppositional defiant disorder (ODD; *n* = 711), attachments disorder (*n* = 154), pervasive developmental disorder (PDD; *n* = 557), personality disorders (*n* = 2,872), speech disorder (*n* = 336,763), and tic disorders (*n* = 154). Mental disorders of children were diagnosed by clinicians or reported by parents/caregivers or children/adolescents.

Risk of Bias and Applicability {#S3.SS3}
------------------------------

The NOS total scores per-study ranged from 3 to 9 (N column in [Table 2](#T2){ref-type="table"}). Twenty-five studies had high methodological quality (NOS score of 7 or higher), whilst 10 studies had moderate quality (NOS score 3--6). The component NOS scores are reported in [Supplementary Appendix 1](#SM1){ref-type="supplementary-material"}.

Meta-Analysis {#S3.SS4}
-------------

Children and adolescents with AD had an overall statistically significant increased risk of total mental disorders compared with those without AD (OR = 1.652; 95% CI, 1.463--1.864; *Z* = 8.112, *p* \< 0.001). The assumption of homogeneity was rejected (*Q* = 454.874, *p* = 0.000), as approximately 93% total variance among studies was due to heterogeneity (*I*^2^ = 92.53%). See [Figure 2](#F2){ref-type="fig"} for a summary of individual study effects and summary effects and the heterogeneity.

![Effect sizes for total mental disorders.](fpsyg-10-01773-g002){#F2}

More specifically, compared with children without AD, suffering AD was significantly associated with higher risks of experiencing ADHD (OR = 1.563; 95% CI, 1.382--1.769; *Z* = 7.095, *p* \< 0.001); sleep disorders (OR = 2.100; 95% CI, 1.322--3.336; *Z* = 3.144, *p* \< 0.01); anxiety (OR = 1.339; 95% CI, 1.062--1.687; *Z* = 2.471, *p* \< 0.05); depression (OR = 1.402; 95% CI, 1.256--1.565; *Z* = 6.012, *p* \< 0.001); conduct disorder (OR = 1.494; 95% CI, 1.230--1.815; *Z* = 4.049, *p* \< 0.001); and ASD (OR = 2.574; 95% CI, 1.469--4.510; *Z* = 3.305, *p* \< 0.01) (see [Supplementary Appendix 2](#SM1){ref-type="supplementary-material"}). There was no statistically significant difference in risk of suffering any of these mental disorders (*Q*~b~ = 8.344, *p* = 0.138) in children with AD. Effect sizes for affective disorder, eating disorder, and ODD were not significant, and effect sizes for attachment disorder, PDD, personality disorder, speech disorder, and tic disorders are not presented, as there was only one study which reported on each of these outcomes.

Publication Bias {#S3.SS5}
----------------

Visual inspection of the funnel plot (see [Supplementary Appendix 3](#SM1){ref-type="supplementary-material"}) and the findings of the Egger test indicated no significant publication bias (*t* = 1.020, *p* = 0.315). The unbiased effect size (OR = 1.500; 95% CI, 1.329 to 1.694) was marginally smaller than the calculated effect size (OR = 1.652). The classic fail-safe number indicated that 4,591 studies with null findings needed to be added to negatively impact (overturn) the overall-effect *p*-value.

Moderators of Risks of Mental Disorders in Children With AD {#S3.SS6}
-----------------------------------------------------------

Total sample size (*Q*~b~ = 6.687, *p* = 0.083) and year of publication (*Q*~b~ = 2.336, *p* = 0.126) did not significantly contribute to between-group variance. [Table 4](#T4){ref-type="table"} presents the analysis of potential categorical moderators.

###### 

Moderator variables analysis.

  **Moderators**                                  ***k***   **Random Effect Size**   **Heterogeneity**                   
  ----------------------------------------------- --------- ------------------------ ----------------------- ----------- --------
  **Sample size**                                                                    ***Q*~*b*~ = 6.687**    **0.083**   
  Less than 100                                   6         2.419 (1.605, 3.647)     5.637                   0.343       11.306
  100--1000                                       8         2.046 (1.397, 2.997)     28.467                  0.000       75.410
  1001--10000                                     11        1.518 (1.308, 1.761)     16.572                  0.084       39.656
  More than 10000                                 10        1.477 (1.228, 1.777)     374.917                 0.000       97.599
  **Year of publication**                                                            ***Q*~*b*~ = 2.336**    **0.126**   
  Earlier than or in 2010                         11        1.944 (1.532--2.468)     21.936                  0.015       54.413
  Later than 2010                                 24        1.568 (1.365--1.802)     427.818                 0.000       94.624
  **Mean age**                                                                       ***Q~*b*~* = 2.626**    **0.269**   
  0--6 years                                      6         1.829 (1.118, 2.993)     29.474                  0.000       83.036
  7--11 years                                     11        1.641 (1.347, 1.999)     53.168                  0.000       81.192
  12--18 years                                    6         1.364 (1.151, 1.616)     1.430                   0.921       0.000
  **Sex of child**                                                                   ***Q*~*b*~ = 0.099**    **0.753**   
  Predominantly male (\> 50%)                     20        1.488 (1.316--1.681)     120.600                 0.000       84.245
  Predominantly female (\> 50%)                   11        1.536 (1.314--1.794)     19.937                  0.030       49.843
  **Race/ethnicity of child**                                                        ***Q~*b*~* = 4.963**    **0.026**   
  Predominantly Caucasian (\> 50%)                4         1.287 (1.017--1.630)     27.662                  0.000       89.155
  Predominantly minority (\> 50%)                 9         1.872 (1.487--2.355)     112.859                 0.000       92.912
  **Family SES**                                                                     ***Q*~*b*~ = 0.418**    **0.518**   
  More than 20% low SES families                  8         1.458 (1.220, 1.743)     13.279                  0.066       47.286
  Less than 20% low SES families                  9         1.356 (1.192, 1.543)     40.365                  0.000       80181
  **HDI in 2018**                                                                    ***Q~*b*~* = 1.974**    **0.160**   
  Developed countries or territories              29        1.559 (1.376, 1.768)     408.119                 0.000       93.139
  Developing countries or territories             5         2.190 (1.387--3.457)     10.518                  0.033       61.971
  **GNI per capital in 2017**                                                        ***Q*~*b*~ = 2.188**    **0.139**   
  High income countries                           25        1.528 (1.333, 1.752)     306.686                 0.000       92.174
  Middle or low income countries                  5         2.190 (1.387, 3.457)     10.518                  0.033       61.971
  **Type of study**                                                                  ***Q~*b*~* = 19.464**   **0.000**   
  Cohort                                          11        1.362 (1.088--1.704)     262.520                 0.000       96.191
  Case-control                                    12        2.809 (2.081--3.790)     26.845                  0.005       59.024
  Cross-sectional                                 12        1.386 (1.242--1.547)     45.166                  0.000       75.645
  **Target of comparison**                                                           ***Q~*b*~* = 32.464**   **0.000**   
  Health control                                  6         3.144 (2.525--3.195)     2.736                   0.741       0.000
  General population                              19        1.477 (1.256--1.725)     286.948                 0.000       93.727
  People with other conditions                    9         1.565 (1.239--1.977)     63.657                  0.000       87.433
  **Representativeness of the sample**                                               ***Q~*b*~* = 6.359**    **0.012**   
  Convenience sample/clinical sample              12        2.211 (1.671--2.925)     24.159                  0.012       54.469
  Random sample/community sample                  22        1.483 (1.297--1.696)     392.730                 0.000       94.653
  **Equivalence of patients and control group**                                      ***Q~*b*~* = 3.255**    **0.071**   
  Yes                                             16        1.903 (1.548--2.287)     124.684                 0.000       87.970
  No                                              19        1.511 (1.274--1.792)     284.734                 0.000       93.678
  **Assessment of AD**                                                               ***Q~*b*~* = 8.089**    **0.018**   
  Diagnosed by a doctor or professional           19        1.904 (1.562--2.322)     139.674                 0.000       87.113
  Self/parental report of doctoral diagnosis      10        1.439 (1.161--1.784)     262.994                 0.000       96.578
  Questionnaire                                   5         1.318 (1.118--1.553)     5.145                   0.273       22.257
  **Rater of mental disorders**                                                      ***Q*~*b*~ = 10.600**   **0.005**   
  Child/adolescent                                5         1.331 (1.257--1.409)     0.384                   0.984       0.000
  Parent/caregiver                                15        1.849 (1.481--2.308)     114.477^∗∗∗^            0.000       87.770
  Clinician                                       13        1.632 (1.321--2.018)     296.077^∗∗∗^            0.000       95.947
  **Assessment of Quality**                                                          ***Q*~*b*~ = 2.507**    **0.113**   
  High methodological quality                     25        1.484 (1.445--1.525)     410.627                 0.000       94.614
  Moderate methodological quality                 10        1.339 (1.245--1.441)     37.554                  0.000       76.034

k = number of studies; 95% CI = lower and upper limits if 95% confidence interval;

Qw/Qb

= test for homogeneity of effect sizes within (w) and between (b) groups.

For demographic factors, race/ethnicity was a significant moderator (Predominantly minority race \> Predominantly Caucasian; *Q*~b~ = 4.963, *p* = 0.026). However, mean age (*Q*~b~ = 2.626, *p* = 0.269) and gender (*Q*~b~ = 0.099, *p* = 0.753) did not significantly contribute to between-group variance.

For socioeconomic factors, family SES (*Q*~b~ = 0.418, *p* = 0.518), HDI (*Q*~b~ = 1.974, *p* = 0.160), and GNI per capital (*Q*~b~ = 2.188, *p* = 0.139) did not significantly contribute to between-group variance.

For methodological factors, the comparator group (healthy control group \> people with other conditions \> general population; *Q*~b~ = 32.464, *p* = 0.000), type of study (*Q*~b~ = 19.464, *p* = 0.000; case control studies \> cohort studies \> cross-sectional studies), and representativeness of the sample (convenience or clinical samples \> randomly selected or community samples; *Q*~b~ = 6.359, *p* = 0.012) contributed significantly to between-group variance. Also, assessment of AD (diagnosed by a doctor or health professional \> self/parental report of doctoral diagnosis \> questionnaire; *Q*~b~ = 8.089, *p* = 0.018) and raters of mental disorders (parents or caregivers \> clinicians \> self-reported; *Q*~b~ = 10.600, *p* = 0.005) contributed significantly to between-group variance. However, equivalence of patients and control group (*Q*~b~ = 3.255, *p* = 0.071) and quality of studies (*Q*~b~ = 2.507, *p* = 0.113) were not statistically significant as moderators.

Discussion {#S4}
==========

Skin as the largest organ of our body constitutes the boundaries between internal and external environments ([@B61]). Besides biological symptoms, children with AD are more likely to encounter psychological challenges than their healthy peers. This meta-analysis of 35 studies (*n* = 1,935,147 children/adolescents) found that AD could result in higher risk of mental disorders among children and adolescents by providing conclusive evidence that children with AD were, on average, 65.2% more likely to develop mental disorders, compared with children without AD.

Previous studies have attempted to explore the mechanisms in which how AD impacts the psychological well-being of children. First, symptoms and characteristics of AD, such as severe and constant pruritus, chronic and relapsing nature, chronic inflammation, and high risk of atopic or allergic comorbidity may directly explain the elevated risk of mental disorders in children with AD ([@B55]; [@B28]). Sleep disorders caused by pruritus may further strengthen the impact of AD on mental health of sufferers ([@B53]). Pediatric AD may also indirectly induce mental disorders through dysfunctional social relationships ([@B12]; [@B20]). In fact, recent studies have suggested that the relationships between suffering AD and mental disorders could be reciprocal ([@B18]; [@B6]). Mental disorders may cause, induce, or exacerbate the physical symptoms of AD through decreased tolerance of pruritus, pain, and disfigurement; and lower adherence to medical treatment ([@B12]). Mental disorders can further cause adverse outcomes such as educational and career impairments, and increased risk for suicide in children with AD ([@B22]; [@B33]).

Topical therapies for treating physical symptoms are commonly the first line in the management of pediatric AD ([@B57]). The high risk of mental disorders in children with AD, and the resultant negative consequences make it clear that successful management of pediatric AD requires a multipronged approach including psychological input, rather than just the medical treatments of physical symptoms ([@B25]). Indeed, there has been growing interest in integrative medicine (IM) to manage pediatric AD in healthcare settings ([@B9]). This approach addresses healing of the whole person, including both physical, psychological, and social dimensions ([@B7]; [@B37]). There would also seem to be a strong indication that working with the psychological dimensions of children should be an integral and routine part of the management of AD ([@B12]). Mental health care adjunctive to medical treatments has great potential to help children with AD to manage itching and scratching, increase adherence to skin-directed care, develop coping competencies, accept their disease and themselves emotionally, and improve quality of life ([@B25]). Addressing emotional distress of children with AD may be an important key to break the vicious cycle of AD and mental disorders in children.

The findings of this review suggest the need for greater inclusion of effective mental health care into holistic management of AD and the importance of multidisciplinary cooperation. On the one hand, health care professionals including dermatologists, allergists, pediatricians, and primary care physicians require a greater understanding of the risk of mental disorders in children with AD ([@B32]). When treating children with severe AD, screening procedures for identifying mental disorders should be emphasized in conjunction with medical treatment ([@B19]). On another hand, mental health professionals including psychiatrists, psychologists, and social workers should give further attention to the symptoms of AD when treating mental disorders of children and adolescents, and also provide effective mental health care to children with AD. Additionally strategies such as listing and recommending mental health care in treatment or management guidelines of pediatric AD and increasing insurance coverage of mental health care for children in health care system should be considered.

Moreover, this study has significant implications for future practice and research. First, this study provided stronger evidence to point toward positive associations between pediatric AD and different types of mental disorders, such as ASD (OR = 2.574); sleep disorders (OR = 2.100); ADHD (OR = 1.563), conduct disorder (OR = 1.494), depression (OR = 1.402), and anxiety (OR = 1.339). The impacts of pediatric AD on different mental disorders were not shown to be significantly different. We suggest that psychological treatments need to target specific mental disorders of children with AD by using different techniques, rather than providing ubiquitous treatment, or just focusing on ADHD. Second, this study found that social-demographic factors including age, gender, and family/country SES did not moderate the impact of AD on mental disorders of sufferers. Mental health care should be developed for, and accessed by, young children and adolescents of both genders, from all family SES, and in both developed countries and developing countries. Third, more research focus is required on Non-Caucasian children since studies on children from minority races predominantly yielded larger effect size than those with predominantly Caucasian children. Fourth, this study found that studies with parents or caregivers as raters of mental disorders yielded larger effect size than those with clinicians or children themselves as raters. Providing daily care to a child with AD usually imposes a heavy psychological burden on parents due to the complex and long-term treatment management ([@B40]). The psychological stress of parents might exaggerate the degree of severity of children's mental disorders in their reports. Only using parents or caregivers as the child's proxy to report on the child's health may induce bias. There is a need to involve the voices of children in future research and practice for moving closer to the best care appropriate for children.

Limitations {#S4.SS1}
-----------

First, a broad range of outcome measures was included to calculate the overall effect size of *Total Mental Disorders*. This resulted in large heterogeneity. We addressed this by conducting independent meta-analyses to assess the effect sizes related to specific mental disorders, and we also employed a more discriminatory random-effects model. Second, gray literature was not included in this meta-analysis. Due to our strict inclusion criteria, we were able to include only a limited number of studies. There were insufficient numbers of studies to support separate meta-analyses for some mental disorders, such as attachment disorders, personality disorders, and tic disorders. Third, the way we assessed for moderator impacts was exploratory, and the results should be interpreted with caution. We could not test for a number of important moderator variables, including medical factors (e.g., severity of AD, onset age and duration of AD, medical treatments received), immunologic factors (e.g., serum immunoglobulin \[IgE\] levels), genetic factors (e.g., family history of AD), and social factors (e.g., social relationships) because too few studies provided this information. More research on these important variables is needed for further investigating the mechanisms that how AD and mental disorders might be interrelated, which would be crucial for improved treatment of both disorders. Additionally, few studies provided information regarding the severity of mental disorders. Future research should explore the association between pediatric AD and different degrees of mental disorders, as not all children may require the same level of support.

Conclusion {#S5}
==========

AD is a disease resulting in significant somatic suffering and psychological disturbance. This meta-analysis identified that children and adolescents with AD had higher risk of mental disorders compared to those without AD. This review highlighted the importance of integrated, holistic, multidisciplinary management of pediatric AD, which emphasizes the well-being of the whole person.
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